Artificial Intelligence | News | Insights | AiThority
Bitcoin
$11,751.11
+40.73
(+0.35%)
Ethereum
$390.88
-5.15
(-1.3%)
Ripple
$0.29
-0.01
(-1.96%)
Litecoin
$57.38
-0.74
(-1.27%)
EOS
$3.04
-0.02
(-0.56%)
Cardano
$0.15
-0
(-2.8%)
Stellar
$0.11
0
(+1.43%)
NEO
$13.14
+0.13
(+1%)
NEM
$0.06
0
(+1.7%)
DigitalCash
$97.47
-0.45
(-0.46%)
Tether
$1.00
0
(0%)
Binance Coin
$22.51
-0.28
(-1.23%)
QTUM
$2.76
+0.02
(+0.82%)
Verge
$0.01
-0
(-1.79%)
Ontology
$0.82
+0.1
(+14.13%)
ZCash
$93.35
-2.58
(-2.69%)
Steem
$0.22
0
(+0.54%)

OncoImmunity Receives €2.2 Million to Roll out Its Machine-Learning Platform to Enable the Development of Personalized Cancer Immunotherapies

0 4

The bioinformatics company OncoImmunity has been awarded the prestigious EU SME Instrument funding. The company’s flagship product, the ImmuneProfiler™, is a unique machine learning solution that has made inroads into solving the neoantigen prediction challenge. OncoImmunity enables their partners to solve the “needle in the haystack” challenge of identifying the right cocktail of neoantigens for each individual patient, and design a vaccine or cell therapy uniquely tailored to their specific tumor.

Read More:  Leveraging the Real ‘A’ in AI to Gain a Business Advantage

The machine learning company is based in both Oslo Norway and Cambridge Massachusetts in the USA, and this funding will advance further its capability to tailor the ImmuneProfiler for specific vaccine platforms, facilitating the design of safer and more efficacious personalized cancer vaccines.

Read More: Interview with Domenic Venuto, Chief Operating Officer of Amobee

– This project matches our ambition to position OncoImmunity as the leading supplier of neoantigen identification software in the personalized cancer vaccine market, says Dr. Richard Stratford, Chief Executive Officer and Co-founder of OncoImmunity.

– The ImmuneProfiler™ is already a powerful antigen presentation prediction tool, with demonstrated utility in predicting antigens that are presented and visible to a patient’s T cells. With these funds OncoImmunity will further advance its generic platform to learn the precise constellation of potential neoantigens that are immunogenic in different vaccine delivery systems, says Dr. Trevor Clancy, Chief Scientific Officer and Co-founder of OncoImmunity.

Read More: Interview with Sheldon Fernandez, CEO at DarwinAI

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.